

PB60534USW

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: P.K. RAND

Serial No.: 10/595,617

Group Art Unit:

File Date:

Examiner:

For: A Hand-Held Capsule Device

Director of the U.S. Patent and Trademark Office
P.O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Applicants request that the references identified on Form PTO-1449 appended hereto be considered by the Examiner and officially made of record in accordance with the provisions of 37 CFR 1.97

- ☒ Copies of the references are enclosed: Ref. 29-46
☐ Copies of the references were submitted in parent application _____ (37 CFR 1.98(d))
☐ A copy of the International Search Report which issued on International Application No. _____ is submitted herewith. All of the publications cited in the International Search Report are listed on the attached form PTO-1449 and Applicants understand that copies have been supplied to the U.S. Patent Office by the International Bureau.

- A. ☒ The Information Disclosure Statement submitted herewith is being filed within three months of the filing date of the above application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, whichever event occurs last. 37 CFR 1.97(b).
- OR
- ☐ The Information Disclosure Statement submitted herewith is being filed before the mailing of a first office action or after the filing of a Request For Continued Examination under 37 C.F.R. 1.114 (37 C.F.R. 1.97(b)(4)).
- B. ☐ The Information Disclosure Statement transmitted herewith is being filed **after** three months of the filing date of the above application or the date of entry into the national stage as set forth in § 1.491 of an international application or after the mailing date of the first Office Action on the merits, whichever event occurred last, but **before** the mailing date of either:
- (1) a final action under § 1.113 or
 - (2) a notice of allowance under § 1.311, whichever occurs first.
- ☐ Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
- ☐ Applicant elects the option to pay the fee set forth in 37 CFR 1.17(p) for submission of an Information Disclosure Statement under § 1.97(c) (\$180.00).
- C. ☐ The Information Disclosure Statement transmitted herewith is being filed **after** a final action under § 1.113, or a notice of allowance under § 1.311, whichever occurs first, but before the payment of the issue fee. Also enclosed is a copy of the International Search Report which issued on International Publication No.

In accordance with the requirements of 37 CFR 1.97(d):

- ☐ Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a

counterpart foreign application not more than three months prior to the filing of this statement.


☐ Applicant hereby petitions for the consideration of the accompanying Information Disclosure Statement. 37 CFR 1.97(d)(ii).

☐ The petition fee set forth in § 1.17(i)(1) (\$130.00) is submitted herewith.

☒ Please charge any required fees to Deposit Account No.07-1392.

☐ A duplicate copy of this paper is attached.

Respectfully Submitted,



J. Scott Young
Registration No. 45,582

Date:
GlaxoSmithKline
Corporate Intellectual Property
5 Moore Drive, P.O. Box 13398
Research Triangle Park, NC 27709-3398
Telephone: (919) 483-8160
Facsimile: (919) 483-7988

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT				SERIAL NO.		10/595,617	
				FILING DATE		Concurrently Herewith	
				APPLICANT		RAND	
				GROUP			
				EXAMINER			
				ATTORNEY DOCKET NO.		PB60534USw	
U.S. PATENT DOCUMENTS							
Examiner Initials		Patent Number	Issue Date	Name	Class	Subclass	Filing Date If Appropriate
	1	1,410,556	Mar. 28, 1922	Dorment			
	2	2,587,215	Feb. 26, 1952	Priestly			
	3	2,590,832	Mar. 25, 1952	Brown			
	4	2,642,063	June 16, 1953	Brown			
	5	4,095,587	June 20, 1978	Ishikawa			
	6	4,391,590	July 05, 1983	Dougherty			
	7	4,446,862	May 08, 1984	Baum et al.			
	8	4,767,326	Aug. 30, 1988	Bennett et al.			
	9	4,815,625	Mar. 28, 1989	Pilhol et al.			
	10	5,048,514	Sept. 17, 1991	Ramella			
	11	5,287,850	Feb. 22, 1994	Haber et al.			
	12	5,372,128	Dec. 13, 1994	Haber et al.			
	13	5,379,763	Jan. 10, 1995	Martin			
	14	5,562,918	Oct. 8, 1996	Stimpson			
	15	5,595,175	Jan. 21, 1997	Malcher et al.			
	16	5,617,971	Apr. 8, 1997	Eason et al.			
	17	5,673,686	Oct. 7, 1997	Villax et al.			
	18	5,727,546	Mar. 17, 1998	Clarke et al.			
	19	5,769,070	June 23, 1998	Frati et al.			
	20	5,778,873	July 14, 1998	Braithwaite			
	21	5,797,392	Aug. 25, 1998	Keldmann et al.			
	22	5,881,721	Mar. 16, 1999	Bunce et al.			
	23	5,924,417	July 20, 1999	Braithwaite			
	24	6,102,036	Aug. 15, 2000	Zamel et al.			
	25	6,109,261	Aug. 29, 2000	Clarke et al.			
	26	6,470,884	Oct. 29, 2002	Horlin			
	27	6,503,084	Jan. 07, 2003	Evers et al.			
	28	6,708,884	Mar. 23, 2004	Su et al.			
Continue on page _____							
FOREIGN PATENT DOCUMENTS							
		Document Number	Publication Date	Country	Class	Subclass	Translation Yes No
	29	DE 837157	Apr. 21, 1952	DE			X
	30	EP 1245243	Oct. 10, 2002	EUROPE			
	31	GB 2323942	Oct. 07, 1998	GB			X
	32	GB 2340758	Aug. 21, 1998	GREAT BRITAIN			
Continue on page _____							
OTHER DOCUMENTS (Including Author, Title, Journal-Date, Page Number, Etc.)							
Continue on page _____							
EXAMINER					DATE CONSIDERED		
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.							

